Ruthenium complexes containing cinnamaldehyde thiadiazole : synthesis, characterization and treatment against cancer

• Grant number: 19/11701-6
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: November 01, 2019
• End date: December 31, 2020
• Field of knowledge: Physical Sciences and Mathematics - Chemistry - Inorganic Chemistry
• Principal Investigator: José Clayston Melo Pereira
• Grantee: Maria Isabella Zachi Soares
• Host Institution: Instituto de Química (IQ). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil

Abstract

Cancer is disease, which caused around 12% of all human deaths worldwide each year. The combination of the two well known drugs, Cisplatin and fluorouracil, has been used for treatment of that disease. However, it have been reported that the enzyme system glutathione/glutathione s-transferases (GSH/GSTs) causes tumor cells resistant to the treatment of cancer. Herein, we propose to use [Ru(Cl)4(DMSO)(TD)] (TD = 1,3,4-Thiadiazol-2-amine, N, N-dimethyl- 5-(2-phenylethenyl)) as alternative drug to cisplatin and fluorouracil. Thus, we propose to synthesize and characterize new complexes of the type [Ru (Cl)4(DMSO)(TD)] (TD = thiadiazole) where thiadiazol can be an anticancer agent. The cytotoxicity effects of these new compounds will be tested in assays using the human tumor cell lines MCF7 (ATCC - HTB-22) and normal cell (ATCC - PCS-201-012).